Publication

Whole-brain activation signatures of weight-lowering drugs

Molecular Metabolism 101171, 2021

Hansen HH, Perens J, Roostalu U, Skytte JL, Salinas CG, Barkholt P, Thorbek DD, Rigbolt KTG, Vrang N, Jelsing J, Hecksher-Sørensen J

Share this page

Resource Library

Related resources

Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson’s disease

Combinations of an Acetyl Coenzyme-A Carboxylase Inhibitor, FXR Agonist, and GLP-1R Agonist Inhibit Fibrosis Progression in the Rat Choline-Deficient, L-Amino-Acid–Defined, High-Fat Diet Model of Advanced Fibrosis

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

Nephroprotective effects of semaglutide in a mouse model of hypertension-accelerated diabetic kidney disease

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650